Figures & data
Table 1 Risk factors for infection with community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)Citation2,Citation3,Citation16,Citation17
Table 2 In vitro activity of select antimicrobial agents against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)
Table 3 Antimicrobials recommended for outpatient treatment of suspected methicillin-resistant (MRSA) skin and skin structure infections
Selection of empiric therapy should be guided by local susceptibility and modified based on results of culture and susceptibility testing. The duration of therapy for most SSSI is 7–10 days, but may vary depending upon the severity of infection and clinical response. Some infections may require a more prolonged treatment course.
Table 4 Parenteral agents for the treatment of severe community-associated methicillin-resistant Staphylococcus aureus infectionsCitation34,Citation43,Citation48,Citation57,Citation85
Table 5 Investigational agents with in vitro activity against methicillin-resistant Staphylococcus aureus
Figure 1 Outpatient management of suspected community-associated methicillin-resistant Staphylococcus aureus skin and skin structure infections. Adapted from Aurora Health Care MRSA Clinical Guidelines 2008. Kathryn Leonhardt, MD, MPH, Editor.
Abbreviations: I&D, incision and drainage; MRSA, methicillin-resistant S. aureus; CA-MRSA, community-associated MRSA.
![Figure 1 Outpatient management of suspected community-associated methicillin-resistant Staphylococcus aureus skin and skin structure infections. Adapted from Aurora Health Care MRSA Clinical Guidelines 2008. Kathryn Leonhardt, MD, MPH, Editor.Abbreviations: I&D, incision and drainage; MRSA, methicillin-resistant S. aureus; CA-MRSA, community-associated MRSA.](/cms/asset/ed67ae17-c3d1-4fa7-96c3-b1b17c184eaf/didr_a_3794_f0001_b.jpg)